Tuesday July 19, 9:30 am ET

Serum Proteins From Patients to be Studied to Distinguish ALS, Alzheimer's and Parkinson's diseases

THE WOODLANDS, Texas, July 19 /PRNewswire-FirstCall/ -- Power3 Medical Products, Inc. (OTC: PWRM.PK - News) has entered into a research agreement with The Methodist Hospital Research Institute to search for biomarkers and develop a suite of tests that directly impact the diagnosis of neurodegenerative diseases. Power3, in collaboration with Stan Appel, M.D., Chair of Neurology at the Methodist Neurological Institute, has completed clinical validation, testing serum proteins from over 600 patients, normal and neurodegenerative disease controls, including patients with Lou Gehrig's (ALS), Alzheimer's and Parkinson's diseases.

The collaborative team has applied the latest proteomic techniques to the differential diagnosis of neurodegenerative diseases utilizing blood serum. Dr. Appel, a renowned and recognized global leader in neuromuscular and neurodegenerative disease research, has been working in concert with Dr. Ira L. Goldknopf, Chief Scientific Officer, and others on the Power3 team to further validate these biomarkers.

"With the signing of this research agreement, we are continuing our collaboration with Dr. Stan Appel and his neurology team at The Methodist Hospital's Neurological Institute," said Steve Rash, Power3 Medical's CEO. "Dr. Appel is the world opinion leader on Lou Gehrig's Disease (ALS) and we are proud of the achievements made to date in our joint efforts to develop early diagnostic and treatment methods for ALS, Alzheimer's and Parkinson's diseases. We look forward to continuing our long and productive relationship with Stan and his team."

According to Dr. Goldknopf, "With this suite of tests, which involve monitoring the concentration of 34 proteins in the blood, we are able to identify unique biomarkers with profiles that appear to distinguish patients with Lou Gehrig's (ALS), Alzheimer's and Parkinson's diseases from one another, as well as from normal patients and patients with other motor neuron and neurological disorders. To our gratification, the specificity and sensitivity of these tests continue to exceed our expectations. In fact, we anticipate filing our second Pre-IDE application with the FDA for a specific test for ALS vs. ALS like disorders in the near term."

Dr. Appel noted, "The proteins identified in conjunction with Power3 represent promising biomarkers for ALS, Alzheimer's and Parkinson's diseases. A main problem to date is that there is a lack of biomarkers and tests for early diagnosis, prognosis, and guidelines for therapy for neurodegenerative diseases. We are pleased with the progress that we have made, and feel these biomarkers and tests offer great promise for improving the clinical outcomes of our patients."

Power3 is proceeding to evaluate serum from additional samples and plans to publish the interesting and promising results later this year.

About Power3 Medical Products

Power3 Medical Products, http://www.Power3Medical.com , is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

This press release contains "forward-looking" statements, including statements related to the outcome of certain actions being taken by the Company and the anticipated timing and nature of filings with the Securities and Exchange Commission. Any statements in this press release, which are not statements of historical fact, may be deemed to be forward-looking statements. Words such as "will," "expects," "anticipates," "plans," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors and uncertainties that could cause results to differ materially from those indicated by these forward-looking statements, including risks inherent in research and development activities; the ability to raise sufficient capital and obtain financing for the development activities; uncertainties associated with regulatory approvals; as well as other risks detailed from time to time in Power3's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003, and its reports on Form 10-QSB and Form 8-K. Power3 assumes no obligation to update forward-looking statements as a result of new information, future events or otherwise.
 

[Back] [Home] [Top]